Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting
- Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in a planned Phase 2a trial in non-small-cell lung cancer (NSCLC).
- Under the agreement terms, Galecto will fund and conduct a Phase 2a trial to investigate the combination of GB1211 and Roche's atezolizumab (Tecentriq) for the treatment of first-line NSCLC.
- The Company plans to initiate the Phase 2a combination study during 1H of 2022 and anticipate topline data in mid-2023.
- The phase 2a trial of GB1211 in combination with Tecentriq will be a 1:1 randomized, double-blind, placebo-controlled trial in up to 70 patients.
- The trial is designed to evaluate safety and tumor shrinkage; additionally, it will explore tumor response, clinical activity, and immune biomarkers.
- Price Action: GLTO shares are down 1.78% at $3.31 during the market session on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Non-Small Cell Lung CancerBiotech News Penny Stocks Health Care Contracts General
